Trials / Completed
CompletedNCT00996372
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
24-wk Efficacy and Safety of Flibanserin vs Pbo in Naturally Postmenopausal Women in United States
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 949 (actual)
- Sponsor
- Sprout Pharmaceuticals, Inc · Industry
- Sex
- Female
- Age
- 35 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | flibanserin | patients will be randomized to flibanserin or placebo in a double-blind manner |
| DRUG | placebo | patients will be randomized to flibanserin or placebo in a double-blind manner |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2011-03-01
- Completion
- 2011-03-01
- First posted
- 2009-10-16
- Last updated
- 2014-06-12
- Results posted
- 2014-06-12
Locations
75 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00996372. Inclusion in this directory is not an endorsement.